MinION is the first commercialized nanopore-based sequencer for sequencing DNA ([@bib15]). It records, in real time, changes in electric current as an applied electrical field drives single-stranded DNA (ssDNA) through ∼500 nanopores assembled on the memory stick--sized device. The MinION DNA library preparation and data analysis pipeline is designed to sequence and analyze, in parallel, ultra-long DNA fragments as long as 100 kb ([@bib21]). The ultra-long-read-length sequences generated by MinION have been used for *de novo* genome assembly and non-reference scaffold building ([@bib19]; [@bib1]; [@bib10]; [@bib12]). We hypothesize that using nanopore sequencers to sequence short DNA fragments could enable real-time rapid and parallel sequencing of many-fold more reads in a given time compared with long-fragment sequencing and thereby enable a wide range of new research and clinical applications such as prenatal and preimplantation diagnosis of aneuploidy in an office setting as well as small DNA and amplicon sequencing in the field or clinic.

In the standard MinION sequencing protocol, DNA is fragmented to an average length of \>6 kb. DNA ends are then repaired and dA-tailed, and the resulting long DNA fragments are ligated to a kit adapter mix. The adapter mix consists of two DNA adapters: a Y-shaped adapter and a hairpin-shaped adapter ([Figure 1A](#fig1){ref-type="fig"}). The Y-shaped adapter has a leader strand that guides DNA to the nanopore and a preattached E5 motor protein that separates the complementary DNA strands and aids in passage of DNA through the pore. The hairpin-shaped adapter enables a "U-turn" at the hairpin and continued sequencing of the complementary strand of a double-strand DNA (dsDNA). The structure of the Y-adapter/template/hairpin-adapter allows the sequencer to generate a template read, a complementary read, and a calibration of these two reads (*i.e.*, a two-dimensional read for dsDNA). The two-dimensional (2D) reads improve sequencing quality from a single dsDNA molecule ([@bib5]; [@bib10]). A His-tagged E3 motor protein, attached to the hairpin-shaped adapter during the ligation process, slows sequencing speeds of the complementary strand and is used for purification of DNA fragments ligated to the hairpin-shaped adapter using His-tag bead purification. Although the parallel sequencing capacity of MinION (512 channels) is much lower than that of other platforms (*e.g.*, Illumina MiSeq, 25 × 10^6^, and Life Technologies Ion Proton, 80 × 10^6^), MinION sequences individual nucleotides at a much faster rate (1200--1800 nt/min) compared with Ion Proton and MiSeq (1 and 0.17 nt/min, respectively). Nanopore-based sequencing also has the distinct advantages that after completing sequencing of one DNA fragment, sequencing of another DNA fragment begins, and reads are generated in real time so that sequencing can be stopped when sufficient reads are obtained.

![MinION short-fragment sequencing library preparation and optimization. (A) Schematic of the short-fragment sequencing library preparation. dsDNA (purple) is fragmented, size selected, end repaired, and concentrated. Increased concentrations of Y-shaped adapters (blue) with attached E5 proteins (orange) and hairpin adapters (red) are ligated onto the dsDNA, and E3 proteins (green) bind to the hairpin adapters. Electric current then drives a single strand of DNA through the nanopore (light gray). (B) Optimization of short-fragment library preparation. Lane 1, control DNA fragment; lane 2, ligation of control fragment and adapters using manufacturer's protocol; lanes 3--7, incremental improvements in ligation efficiency using purification of fragmented and dA-tailed template DNA (lane 3), reduced reaction volume (lane 4), incorporation of a 1- to 2-hr incubation at 4° (lanes 5 and 6), and reducing room-temperature incubation time to 5 min to reduce release of E5 proteins from adapters (lane 7).](37fig1){#fig1}

MinION nanopore genomic DNA library preparation and sequencing protocols were developed for long-fragment sequencing and consequently cannot be used for short-fragment library preparation directly. Moreover, because a short-fragment sequencing run generates significantly more individual reads within a given time than a long-fragment sequencing run, optimization of data analysis was required. However, the rapid quantification of short reads is of particular importance in some sequencing applications, such as ultra low-coverage sequencing (ULCS) for aneuploidy detection and identification of pathogens ([@bib9]; [@bib18]; [@bib6]; [@bib3]; [@bib22]). As part of the MinION access program (MAP), we were given early access to beta test and develop the MinION. In this study, we explore the possibility of using a MinION nanopore sequencer as an ultra-portable device for rapid short-read sequencing. Here we report a library preparation and data-analysis method to enable rapid short-length sequencing on MinION nanopore sequencers and demonstrate its clinical applicability for aneuploidy detection in amniocentesis and miscarriage samples.

Materials and Methods {#s1}
=====================

Development of ligation conditions {#s2}
----------------------------------

To assess the ligation efficiency, a short DNA control fragment was used for initial ligation reactions (Supporting Information, [Table S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS1.pdf)). The fragment was generated using PCR with M13 forward and reverse primers to amplify a 434-bp fragment from a pCR-Blunt vector (Invitrogen, cat. \#K2700-20) using Q5 High-Fidelity DNA Polymerase (NEB, cat. \#M0491S) ([Table S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS1.pdf)). A 50-μl PCR reaction was prepared following the manufacturer's protocol. The PCR reaction was subjected to a 30-sec initial denaturation at 98°, 25 cycles of 10-sec denaturation at 98°, a 30-sec annealing at 57°, and a 20-sec elongation at 72°. A final elongation step at 72° for 2 min was added to ensure complete amplification. The PCR product was purified using a QIAquick PCR Purification Kit following the manufacturer's protocol (Qiagen, cat. \#28104). A 57-bp asymmetric adapter with a T overhang was used as a control adapter to assess ligation efficiency ([Table S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS1.pdf)). The control adapters were diluted to 0.4 μM in MinION adaptor buffer (50 mM NaCl and 10 mM Tris-HCl, pH 7.5) to simulate the 0.2-μM concentration of the Y-shaped and hairpin adapters in the adaptor mix (Oxford Nanopore, SQK-MAP004).

Ligation reactions were initially performed following the MinION Genomic Sequencing Kit protocol (Oxford Nanopore, SQK-MAP004). Control DNA fragments (0.2 pmol, 52 ng) were added to a 30-μl NEBNext dA-Tailing Module (NEB, cat. \#E6053S) reaction \[4 μl of control fragments, 21 μl of Qiagen Buffer EB, 3 μl of 10× NEBNext dA-tailing reaction buffer, and 2 μl of Klenow fragments (3′→5′ exo-)\]. Reactions were performed at 37° for 30 min in a Bio-Rad C1000 Touch Thermal Cycler. All the dA-tailing reactions were added to a total volume of 100 μl \[30 μl of dA-tailing reaction, 10 μl of control adapter, 10 μl of nuclease-free water, 50 μl of NEB Blunt/TA Ligase Master Mix (NEB, cat. \#M0367S)\] and incubated at room temperature (23--25°) for 10 min.

Because so few control fragments had adapters ligated on both ends ([Figure 1B](#fig1){ref-type="fig"}, lane 2), an alternative Klenow fragment (3′→5′ exo-) (NEB, cat. \#M0212S) was used for dA-tailing, and the dA-tailing reactions were purified before being added to the ligation reactions. Control DNA fragments (250 ng) were subjected to a dA-tailing reaction \[2.5 μl of NEBuffer II, 5 μl of 1 mM deoxyadenosine triphosphate (dATP), 1 μl of Klenow fragment (3′→5′ exo-), and nuclease-free water to a total volume of 25 μl\]. After purification with 1.8-fold AMPure XP beads (Beckman Coulter, cat. \#A63880) following the manufacturer's protocol for the SPRIselect reagent (Beckman Coulter, cat. \#B23317), the dA-tailed control fragment was eluted in 12 μl of 1/5 Qiagen Buffer EB (2 mM Tris-Cl, pH 8; Qiagen, cat. \#19086) and diluted to 0.05 μM (13 ng/μl).

Overnight ligation reactions at 16° using T4 DNA ligase (NEB, cat. \#M0202S) to ligate a 10:1 adapter:fragment mixture (4 pmol control adapter, 0.2 pmol control fragment in 2 μl 10× T4 DNA ligase buffer, 1 μl T4 DNA ligase, and nuclease-free water to 20-μl final volume) resulted in ∼75% of the control fragments having adapters on both ends, which would not be sufficient final products for downstream steps. Therefore, the reactions were run in duplicate and combined. Then 5:1 adapter:fragment ratios were used to preserve the adapters provided in the MinION kits.

The second ligation reactions were a replication of the manufacturer's ligation protocol using the purified dA-tailed DNA, as described previously ([Figure 1B](#fig1){ref-type="fig"}, lane 3), using 100 μl of ligation reaction with 0.4 pmol of DNA, 26 μl of Buffer EB, 10 μl of control adapter, 50 μl of Blunt/TA Ligase Master Mix (NEB, cat. \#M0367S), and 10 μl of nuclease-free water (Ambion, cat. \#AM9937). Reactions were incubated at room temperature for 10 min and purified using 1.8-fold AMPure XP beads, washed with the wash buffer in the SQK-MAP003 MinION Genomic DNA Sequencing Kit (750 mM NaCl, 10% PEG 8000, 50 mM Tris-HCl, pH 8.0), and eluted in 20 μl of Buffer EB.

The third ligation reactions were a reduced-volume system using purified dA-tailed DNA, as described previously ([Figure 1B](#fig1){ref-type="fig"}, lanes 4--7). A 20-μl ligation reaction containing 0.2 pmol of DNA (4 μl), 2 pmol of control DNA adaptor (5 μl), 10 μl of Blunt/TA Ligase Master Mix, and 1 μl of nuclease-free water was incubated for 10 min at room temperature, purified using onefold AMPure XP beads with the SQK-MAP003 wash buffer, and eluted in 20 μl of Buffer EB ([Figure 1B](#fig1){ref-type="fig"}, lane 4). Reactions were carried out at room temperature for 5--10 min, followed by 4° incubation for 1--2 hr ([Figure 1B](#fig1){ref-type="fig"}, lanes 5--7). Reactions were purified using onefold AMPure XP beads with SQK-MAP003 wash buffer and eluted in 20 μl of Buffer EB. Purified ligation products were run on 2% agarose gels. Portions of the ligation products were estimated using ImageJ (<http://imagej.nih.gov/ij/>) densitometry analysis with two technical replicates ([Figure S5](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/FigureS5.pdf)).

Nucleic acid manipulations {#s3}
--------------------------

To facilitate maximum recovery of material, 1.5-ml low-retention microcentrifuge tubes (Phenix Research Products, cat \#MH815S) and low-retention tips (Phenix Research Products, TFL series) were used unless stated otherwise ([Figure S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/FigureS2.pdf)). For all reactions performed in a thermal cycler, 0.2-ml PCR tubes were used (Axygen, cat. \#PCR-02-C). An Agencourt SPRIStand Magnetic 6-tube Stand (Beckman Coulter, cat. \#A29182) was used for pelleting of SPRIselect and AMPure XP bead--related purification; a DynaMag-2 magnet (Life Technologies, cat. \#12321D) was used for His-tag bead isolation.

Genomic DNA samples {#s4}
-------------------

Genomic DNA (gDNA) samples from a karyotypically normal male and female, a male with trisomy 12, a male with trisomy 21, and a female with monosomy *X* were used for cytogenetic analysis using short-DNA-fragment ULCS with the MinION. Blood B-lymphocytes from karyotypically normal human male and female samples were obtained from the Coriell Institute Cell Repositories (GM12877 and GM12878) and cultured according to the protocol provided by the Coriell Institute. gDNA was extracted from cell cultures from the second passage using a QIAamp Blood DNA Mini Kit (Qiagen, cat. \#51104) following the manufacturer's manual. gDNA from a male with trisomy 21 was provided by the Coriell Institute Cell Repositories (NG05397). DNA samples from a male with trisomy 12 and a female with monosomy *X* were obtained from the products of conception of miscarriage cases that had cytogenetic testing performed using G-band karyotyping. The studies were approved by the Institutional Review Board of Albert Einstein College of Medicine, and patients' consent was obtained. gDNA was extracted using an AllPrep DNA/RNA/Protein Mini Kit (Qiagen, cat. \#80004) from the trophoblastic primary cell cultures of the chorionic villus. The quality of gDNA was examined on 0.8% agarose gel and quantified using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). DNA was stored at −20° until needed.

Library preparation {#s5}
-------------------

For library preparation, 120 μl of 25 ng/μl gDNA in TE Buffer (pH 8.0) was fragmented using a Covaris S220 focused-ultrasonicator at the manufacturer's 500-bp setting in microTUBEs (Covaris, cat. \#520045). For size selection, 100 μl of fragmented gDNA was used. Size selection was performed in a 1.5-ml DNA LoBind tube (Eppendorf, cat. \#022431021) using SPRIselect reagent following the manufacturer's double-sized selection protocol using a right-side 0.55-fold, left-side 0.7-fold setting (Beckman Coulter, cat. \#B23317). DNA was eluted in 40--50 μl of Buffer EB in a 1.5-ml DNA LoBind tube. Then 2 μl of DNA was used for a 2% gel electrophoresis to confirm fragment size. Purified DNA (3 μl) was saved for NanoDrop quantification. Size-selected DNA fragments were ∼350--600 bp in length ([Figure S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/FigureS1.pdf)C).

Buffer EB was added to size selected DNA to a final volume of 80 μl. End-repair reactions were performed using a NEBNext End Repair Module (NEB, cat. \#E6050S) in a 1.5-ml DNA LoBind tube. Then 5 µl of DNA CS (Oxford Nanopore, SQK-MAP004), 10 µl of 10× NEBNext End Repair Reaction Buffer, and 5 µl of NEBNext End Repair Enzyme Mix were added to the size-selected DNA fragment and mixed by gently pipetting. The reactions were incubated at room temperature for 25 min and purified using 1.8-fold AMPure XP beads following the SPRIselect reagent protocol in a DNA LoBind tube. The end-repaired DNA was eluted in 22 µl of Buffer EB, and the DNA was quantified using a Qubit dsDNA HS Assay Kit (Life Technologies, cat. \#Q32854).

End-repaired DNA was subjected to a dA-tailing reaction using a Klenow fragment (3′→5′ exo-) in a total volume of 25 µl in a sterile PCR tube. The reaction contained 2.5 µl of NEBuffer II, 1 µl of Klenow fragment (3′→5′ exo-), 16.5 µl of end-repaired purified DNA, and 5 µl of dATP (1 mM). Reactions were incubated in a Bio-Rad C1000 Thermal Cycler at 37° for 45 min, purified using 1.8-fold AMPure XP beads, and then eluted in 12 µl of 1/5 Buffer EB. The purified product was quantified using NanoDrop and a Qubit dsDNA HS Assay Kit (Life Technologies, cat. \#Q32854) and diluted to ∼0.05 µM (∼18 ng/µl) with 1/5 Buffer EB to be used as the dA-tailed DNA in subsequent reactions.

His-tag Dynabeads (10 μl) (Invitrogen, cat. \#10103D) were washed in 1.5-ml low-retention tubes in a MinION Genomic DNA Sequencing Kit following the manufacture's protocol on a DynaMag-2 magnetic stand (Invitrogen, cat. \#12321D). Washed beads were resuspended in 40 μl of undiluted wash buffer (SQK-MAP004) and kept on ice. Ligation reactions were performed in a 1.5-ml low-retention tube. Twenty-microliter reactions contain 4 μl of dA-tailed DNA (0.2 pmol), 5 μl of adaptor mix (1 pmol) (SQK-MAP004), 1 μl of HP adapter (1pmol) (SQK-MAP004), and 10 μl of Blunt/TA Ligase Master Mix (NEB, cat. \#M0367S). The reactions were mixed by pipetting gently between each sequential addition and spun down briefly in a benchtop centrifuge. Ligation reactions were incubated at room temperature for 5 min follow by 4° for 2 hr. For each sample, 2 × 20 μl reactions were performed in separate tubes and combined for His-tag bead purification.

In 1.5-ml low-retention tubes, 40 μl of washed His-tag beads were added to the adapter-ligated DNA and carefully mixed by gentle pipetting. The mixture was incubated at room temperature for 5 min and placed on ice for 30 sec. His-tag bead purification was performed following the protocol of the MinION Genomic DNA Sequencing Kit (SQK-MAP004). Pelleted beads were resuspended 28 µl of the ELB elution buffer (SQK-MAP004) by gently pipetting 10 times. The suspension was incubated at room temperature for 5 min and placed on ice for 30 sec, and this was repeated once before placing the suspension back on the magnetic rack for pelleting. The eluate was transferred to a clean 1.5-ml low-retention tube, incubated on ice for 30 sec, and then placed on a magnetic rack for 2 min for pelleting any residual beads. The eluate then was carefully transferred to a 1.5-ml low-retention tube. This library was called the *presequencing mix*. 4 μl of the presequencing mix was used for quantification by a Qubit dsDNA HS Assay Kit.

MinION sequencing {#s6}
-----------------

150 μl of the priming mix (147 μl of EP buffer and 3 μl of fuel mix) was loaded on a MinION Flow Cell (R7.3) and incubated for 10 min. The priming process was repeated once. 150 μl of the MinION sequencing library (12 μl of the presequencing mix, 135 μl of EP buffer, and 3 μl of fuel mix) was gently mixed and loaded to the MinION Flow Cell. The MAP 48-hr gDNA sequencing protocol was used, and the sequencing reaction was stopped when sufficient data were collected.

Data analysis {#s7}
-------------

Metrichor agent v2.26 was used to transfer local fast5 files, and 2D BaseCalling Rev1.14 was used to convert currency into base events (Oxford Nanopore Technologies). Poretools v0.5.0 ([@bib14]) was used to convert Fast5 to fastQ files. The first and last 50 bases were removed from each sequence using cutadapt v1.7.1 ([@bib16]), and sequences that were at least 50 bases long were kept after removal. Both one- (1D) and two-dimensional (2D) reads were aligned to the Ensembl GRCh37 human reference genome using BLAT (<http://www.kentinformatics.com/>) ([@bib11]) ([Table S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS2.pdf)). Fewer than 1% of 1D sequences passed the screening criteria (covers ≥40% of query and ≥80% alignment identity), and consequently, only 2D sequences were used for further analysis. 2D reads with a unique alignment (UA) match to a genomic location were retained for further analysis. Bowtie 2 also was tested for mapping 2D sequences to a human reference genome ([@bib13]). Because Bowtie 2 was designed for high-throughput mapping of short sequences (50--200 bp), fewer than 5% of full-length 2D reads could be mapped. Bowtie 2 bwa-sw--like settings ([@bib13]) developed for Roche 454 pyrosequencing data also were tested, and only 36% of the 2D reads were UA matches (data not shown). Therefore, we used Bowtie 2 to align the first 200 bp of the 2D reads and generated 45% UA matches in ∼1 min ([Table S3](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS3.pdf)). 2D reads also were mapped to the reference genome with LAST (<http://last.cbrc.jp/>) using the settings that were reported to be most inclusive for alignment for MinION long reads ([@bib8]; [@bib19], 2015). However, this produced fewer UA matches than the BLAT pipeline using the same screening criteria ([@bib11]) ([Table S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS2.pdf)). Hence, only the UA matches from the BLAT pipeline were used for the fast cytogenetic analysis with ULCS ([@bib3]).

Digital karyotyping using ULCS {#s8}
------------------------------

ULCS is a powerful tool for cytogenetic analysis ([@bib3]). As a proof of concept, we performed the analysis on five samples, and a modified ULCS strategy was used for this study. A previous study indicated that the coefficient of variation (CV) in ULCS (\<0.01-fold coverage) was lower than 15% on each autosome and that there was no significant difference in the autosomal CVs between the MiSeq and Ion Proton platforms ([@bib3]). In a ULCS analysis, we assumed that the UA match on each chromosome (labeled as subscript i, i = 1, 2, ..., 22, *X*, *Y*) fits the Poisson distribution ([@bib7])$$UA_{i} = n_{i}\varphi_{i}$$where *n*~i~ is the number of reads needed to cover a chromosome i, and φ~i~ is the coverage of a chromosome i. The percentage of UA matches on each chromosome (%UA~i~) is determined by the length and copy number of each chromosome under the same coverage.

The lower limit of sequencing reads needed for ULCS was determined primarily by the UA matches assigned to chromosome *Y* because (1) it is one of the shortest chromosomes, and thus fewer DNA fragments would be sequenced from it, (2) less than 50% of chromosome *Y* has been sequenced and annotated in the human reference genome, and hence more than half the chromosome *Y* reads would not be able to be mapped to the reference genome and then be counted, and (3) reads mapped to identical regions of chromosomes *X* and *Y* would not be considered as UA matches by the analysis pipeline. Moreover, cross-linking between chromosomes *X* and *Y* and the presence of repetitive elements will cause a small portion of misplacement of reads from chromosomes *X* and *Y* that will further reduced reads that could have been mapped to the *Y* chromosome.

To estimate the lower limit of UA~i~ needed for ULCS cytogenetic analysis, we used a normal approximation of the Poisson distribution in R (qpois function) to estimate the detection power of UA matches for aneuploidy([@bib20]) ([Figure 2F](#fig2){ref-type="fig"}.). It was estimated that the when UA~i~ = 41, *p*(*x* \> 1.25λ) = 0.04, *p*(*x* \> 1.5λ) = 0.0008, and the detection power of aneuploidy is 90% ([Figure 2B](#fig2){ref-type="fig"}). When the UA~i~ = 79, the detection power of aneuploidy would be 95.6%. The corresponding total UA matches for UA*~Y~* ∼ 79 is ∼15,000 in the normal male sample. Thus, 15,000 UA matches were randomly selected 30 times from the sequencing result of the normal male, and the average UA matches for each chromosome were used as a reference for normalization purpose (Ref_UA~i~). To examine whether the 15,000 reference is representative of the human genome under a Poisson distribution, we compared the percentage of ungapped length (%UL) and the %UA of each chromosome. The ratio (Norm_Ref\_%UA) on autosomes was 1.04 (SD = 0.0687, CV = 6.6%) ([Table S6](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS6.pdf)). The 15,000 reference represents the %UA of about a half the %UL of the sex chromosomes, which could be the result of depletion of nonunique alignments on homogeneous regions of the sex chromosomes. The mitochondrial chromosome (MT) is a multicopy small chromosome ([@bib17]), and it was not included in the ULCS cytogenetics analysis. According to the Poisson distribution, the 99.9% confidence intervals of each chromosome of the normal male reference can be estimated as ${Re}f\_ UA_{i} \pm 3.29\sqrt{{Re}f\_ UA_{i}}$ under the same coverage.

![Cytogenetic analysis of gDNA using short-DNA-fragment MinION sequencing. (A) Short-DNA-fragment sequencing using MinION was able to correctly determine gender and detect aneuploidy in DNA samples from a normal male and female, a female with monosomy *X*, a male with trisomy 12, and a male with trisomy 21 (*P* \< 0.001). The copy number of each chromosome was reflected by the corrected normalized percentage of UA matches ($Norm^{\prime}\_\% UA_{i}$). Black dots represent chromosomes without significant copy number changes; red dots represent chromosomes with significant copy number changes compared with a normal male reference; dotted line represent 99.9% confidence intervals. (B) Theoretical lower UA required for aneuploidy detection under the Poisson distribution. When λ = 41, *p*(*x* \> 1.5λ) = 0.0008 and *p*~β~(*x*′ \< 1.25λ) = 0.10. (C) Theoretical lower detection power using the 15,000 reference under the Poisson distribution. The *Y* chromosome has the fewest UA matches assigned (79--80). When λ = 79, *p*(*x* \> 1.5λ) = 1.07 × 10^−5^ and *p*~β~(*x*′ \< 1.25λ) = 0.034. (D) Sequencing yield of a short-fragment library across time showing raw reads (gray line), 2D reads (black line), and reads uniquely aligned to the Hg19 reference genome (red).](37fig2){#fig2}

To access the copy number of each chromosome of a query sample using 15,000 UA match reads ([Table S7](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS7.pdf)), we assumed that the number of UA reads on each chromosome (UA~i~) fits the Poisson distribution, as described earlier. Using 15,000 UA reads, the normalized ratio between a query sample and the reference (Norm\_%UA~i~) was determined by the copy number of chromosomes$$Norm\_\% UA_{i} = \frac{Query\_\% UA_{i}}{{Re}f\_\% UA_{i}}~ = ~\frac{Query\_ n_{i} \times ~Query\_\phi_{i}}{{Re}f\_ n_{i} \times ~{Re}f\_\phi_{i}}$$To address the change in coverage, φ due to loss or gain of chromosomes, the corrected normalized %UA~i~ equals$$Norm^{\prime}\_\% UA_{i} = \frac{Norm\_\% UA_{i}}{\overline{Norm\_\% UA_{i}^{\prime}}}$$where $\overline{Norm\_\% UA_{i}^{\prime}}$ is the average Norm\_%UA~i~ of normal autosomes, as determined by *Z*-score. For an unknown sample, the SD of Norm\_%UA~i~ of normal autosomes (SD~normal~) was estimated based on known normal autosomes (within ${Re}f\_ UA_{i} \pm 3.29\sqrt{{Re}f\_ UA_{i}}$) in this study (*n* = 105, SD~normal~ = 0.0489). The *Z*-score was calculated for each chromosome as$$Z - score_{i} = \frac{Norm\_\% UA_{i} - Mean\_\% UA_{autosome}}{SD_{normal}}$$Chromosomes having a $\left| {Z - score} \right| > 3.29$ were considered to be abnormal chromosomes with *P* \< 0.001. When the *Z*-score was greater than 3.29, we consider there to be a gain of a chromosome, and when the *Z*-score was less than −3.29, we consider there to be a loss of a chromosome. While the modified *Z*-score method would be less specific in detecting abnormalities on small autosomes than the *Z*-score method based on a census of each chromosome ([@bib3]), it provided sufficient power for aneuploidy detection (\>95%) ([Figure 2C](#fig2){ref-type="fig"}). The theoretical value of a normal autosome $Norm^{\prime}\_\% UA_{normal}\mspace{9mu} = \mspace{9mu} 1$, that of a full trisomy of an autosome $Norm^{\prime}\_\% UA_{trisomy}\mspace{9mu} = \mspace{9mu} 1.5$, that of a monosomy of an autosome $Norm^{\prime}\_\% UA_{monosomy}\mspace{9mu} = \mspace{9mu} 0.5$, that of the *X* chromosome of a normal female $Norm^{\prime}\_\% UA_{X\_ female}\mspace{9mu} > \mspace{9mu} 1.5$, and that of the *Y* chromosome of a normal female or missing *Y* chromosome $Norm^{\prime}\_\% UA_{Y\_ female}\mspace{9mu} < \mspace{9mu} 0.5$.

We hypothesized that the corrected normalized %UA~i~ ($Norm^{\prime}\_\% UA_{i}$) reflects the copy number of chromosomes. The $Norm^{\prime}\_\% UA_{i}$ values were used to compute the adjusted *Z*-score (*Z*′-score). The $Norm^{\prime}\_\% UA_{i}$ values of normal autosomes with a $\left| {Z - score} \right| > 3.29$ were summarized ($Mean\_ Norm^{\prime}\_\% UA\, = \, 0.9999,\mspace{9mu} SD\_ Norm^{\prime}\_\% UA\, = \, 0.0481$). The *Z*′-score for each chromosome equals$$Z^{\prime} - score_{i} = \frac{Norm^{\prime}\_\% UA_{i} - Mean\_ Norm^{\prime}\_\% UA~}{SD\_ Norm^{\prime}\_\% UA}$$In brief, 15,000 UA matches were randomly selected from the normal male sample---and this was repeated for a total of 30 times---and averaged for normalization purposes (Ref_UA). For each sample, the first 15,000 UA matches (Query_UA) were selected for gender determination and aneuploidy detection. The UA matches were summarized and counted for each chromosome (UA~i~, i = 1, 2, ..., *X*, *Y*), and corresponding percentages were calculated for each chromosome (%UA~i~) by UA~i~/15,000 × 100. The %UA~i~ value for each of the chromosomes of a query sample (Query\_%UA~i~) was normalized to the normal male reference (Ref\_%UA~i~) and corrected to detect the copy number of each chromosome ($Norm^{\prime}\_\% UA_{i}$) ([Table S7](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS7.pdf) and [Figure 2A](#fig2){ref-type="fig"}).

Results and Discussion {#s9}
======================

To maintain equivalent molar concentrations for short-DNA-fragment-length library preparations compared with long-fragment-length preparations, ∼18-fold lower total nanograms of input DNA and improved ligation efficiency were required ([Figure 1B](#fig1){ref-type="fig"}, [Table S5](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS5.pdf)). We systematically modified the protocol to improve ligation efficiency. To monitor ligation reactions, a 434-bp PCR product and a 57-bp control adapter duplex with a T overhang were used ([Table S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS1.pdf)). The intermediate ligation product with one adapter is ∼490 bp, and the final product with adapters on both ends is ∼550 bp. Use of the manufacturer's protocol resulted in \<5% final products ([Figure 1B](#fig1){ref-type="fig"}, lane 2). By purifying dA-tailed DNA prior to ligation, the percentage of final products increased to 25% ([Figure 1B](#fig1){ref-type="fig"}, lane 3). Reducing reaction volumes from 100 to 20 μl further increased the percentage of final products to 48% ([Figure 1B](#fig1){ref-type="fig"}, lane 4). By combining a 10-min room temperature incubation with a 1- to 2-hr incubation at 4°, we were able to increase the percentage of final products to 61--63% ([Figure 1B](#fig1){ref-type="fig"}, lanes 5--7) without releasing the preattached E5 protein. Thus, by purifying and then concentrating dA-tailed DNA to reduce the reaction volume and by introducing a prolonged ligation at 4°, the ligation efficiency of the final products was increased from \<5 to 63% ([Figure 1B](#fig1){ref-type="fig"}, lane 2 *vs.* lanes 6 and 7, [Table S5](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS5.pdf)) and provided sufficient material for downstream His-tag bead purification ([Table S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS2.pdf)).

To determine the optimal tool for data analysis of the increased number of reads obtained with sequencing of short DNA, we compared LAST---an alignment program recommended by MAP---with two similar programs, Bowtie 2 and Blat ([@bib11]; [@bib8]; [@bib13]) using a training library generated through a MinION short-DNA-sequencing run ([Table S3](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS3.pdf)). While Bowtie 2 and LAST completed alignments more quickly (1 and 14 min, respectively) than Blat (68 min), Blat generated more good alignments (65%) compared with Bowtie 2 and LAST (58 and 61%, respectively) for the same data sets, likely due to the tendency for MinION sequencing errors resulting in deletions ([@bib11]; [@bib13]; [@bib10]) ([Table S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS2.pdf), [Table S3](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS3.pdf), and [Figure S3](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/FigureS3.pdf)). Blat also generated more UA matches (62%) than Bowtie 2 and LAST (45 and 55%, respectively). Blat was used for alignment of the MinION short-DNA-sequencing results to provide the most inclusive alignment results. Given sufficient computational resources on a high-performance server, increasing parallel threats can further reduce the run time.

To demonstrate the clinical utility of nanopore-based sequencing of short DNA fragments, we ran a pilot study testing the ability of this approach to diagnose aneuploidy. Fetal aneuploidy testing is routinely performed as a component of prenatal testing \[*e.g.*, amniocentesis and chorionic villus sampling (CVS)\], preimplantation genetic screening (PGS) of embryos in *in vitro* fertilization (IVF), and evaluation of miscarriage tissue ([@bib2]). A rapid diagnosis is clinically vital to enable timely management. In the case of prenatal samples obtained via an amniocentesis or CVS, rapid results will enable treatment before the pregnancy progresses to a more advanced gestational age, when treatment options are more limited, technically difficult, and dangerous to the mother. In the case of PGS, rapid testing will enable transfer of the embryo in a given IVF cycle without the need to freeze embryos. However, standard methods to diagnose aneuploidy, such as karyotyping and microarray analysis, take 7--21 days to complete. ULCS for the detection of aneuploidy is a new strategy for whole-genome aneuploidy detection that requires alignment of reads to a reference genome assembly but still requires 15--21 hr to complete and costly and technically advanced library preparation and sequencing platforms that cannot be readily used in a physician's office or in low-complexity settings ([@bib3]; [@bib22]). The ULCS approach for determining aneuploidy requires only that the reads are sufficiently long to enable unique alignment to the genome. Thus, a method to rapidly sequence large numbers of short DNA fragments in real time would enable rapid diagnosis of aneuploidy in settings outside an advanced laboratory facility.

Purified gDNA samples from a normal male and female, a male with trisomy 12, a male with trisomy 21, and a female with monosomy *X* were fragmented, size selected (350--600 bp), and processed as described earlier ([Table S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS2.pdf)). Sequencing short-DNA-fragment libraries prepared using our protocol with MinION generated ∼500 unique reads after the first 3 min of sequencing and 43,000--87,000 raw reads and 27,000--58,000 2D reads (32--67%) after 4 hr of sequencing ([Figure 2](#fig2){ref-type="fig"} and [Table S4](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS4.pdf)). This compares favorably with the traditional MinION sequencing protocol, which sequenced \<12,000 reads after 36 hr ([@bib19]; [@bib12]). Noninvasive prenatal testing (NIPT) is another potential application of the nanopore sequencing technology that would benefit from our short-DNA-sequencing method. NIPT testing on the MinION nanopore sequencer using the standard protocol took 6--24 hr to generate up to 56,000 2D reads, and 15.6--23.9% of the 2D reads were UA reads ([@bib4]). In contrast, our assay generated up to 58,000 2D reads in \<4 hr, and 39.1--69.7% of the 2D reads were UA reads. Our protocol and data analysis can be very helpful in improving NIPT analysis, including the run time and detection sensitivity ([Table S4](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS4.pdf)).

Using the short-fragment-length DNA sequencing library preparation and analysis pipeline, we obtained sufficient numbers of reads for successful determination of gender and aneuploidy (*P* \< 0.001) in all samples within 2--4 hr ([Figure 2A](#fig2){ref-type="fig"}). Using a normal approximation of the Poisson distribution, the chance of a type II error for detecting aneuploidy (p~β~-aneuploidy) was \<0.05 ([Figure 2C](#fig2){ref-type="fig"} and [Table S7](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.182311/-/DC1/TableS7.pdf)). Because MinION is easily scalable, cytogenetic analysis can be done within 1--2 hr by running two MinION sequencers in parallel. MinION Flow Cells currently cost US\$500--900, although efficiency improvements and multiplexing are likely to bring these costs down in the future. Furthermore, as sequencing chemistry and platforms are being actively improved, faster sequencing speeds (70 *vs.* 30 nt/sec) and platforms with higher throughput in the near future, such as the MinION MkII (4096 channels) and the PromethION (262,176 channels), will enable even faster short-read sequencing with higher coverage.

In summary, in addition to the intended role of MinION for sequencing long fragments of DNA, our results demonstrate that MinION also can be used for very rapid real-time acquisition of short DNA reads that can be used for time-sensitive aneuploidy detection in clinical care as well as sequencing of small DNA fragments and amplicons in the field or clinic. This ability can expand the utility of the MinION into new clinical and research applications.
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